Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...
Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low dise ...
Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according ...
Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.
Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...
Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...
Tralokinumab is effective in severe atopic dermatitis for up to 18 months, with patients who are naïve to some medications having faster benefits.
Nikhil Lalwani, President and CEO of ANI stated, "ILUVIEN's expanded label and the strengthening of our partnership with long ...
Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...
ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN Label
ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME)ANI plans to begin marketing ILU ...
This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results